文献速递结核与非结核分枝杆菌

PaMZ方案疗程的灭绝时间数学预测

Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究用结核中空纤维系统模型比较PaMZ方案与标准三药联合治疗的杀菌速率,并以灭绝时间方程和拉丁超立方抽样推算不同疗程的灭菌患者比例。结果显示PaMZ方案3、4个月疗程的预期灭菌比例分别为40.37%和72.30%,低于标准治疗6个月的93.67%。作者认为PaMZ方案杀菌速率不足以使多数患者在6个月内治愈。

要点

  • PaMZ方案3个月疗程预期灭菌比例仅约40%,不足以覆盖多数患者
  • 标准治疗6个月预期灭菌比例为93.67%,仍优于PaMZ短疗程
  • 该结论来自中空纤维模型与数学建模,需临床验证

核心结论

  • PaMZ方案的杀菌速率被预测不足以使多数患者在6个月以内达到治愈。

研究设计与样本

  • 采用结核中空纤维系统模型开展系列实验,分别对对数生长期菌处理28天、胞内菌每日处理28天、半休眠结核分枝杆菌每日处理56天以评估灭菌效果。
  • 随后使用灭绝时间方程,结合形态学变换与拉丁超立方抽样,推算各方案达到3、4或6个月灭绝时间的患者比例。

主要发现

  • 56天内PaMZ方案与标准治疗方案的HFS-TB灭菌速率分别为0.18(95%可信区间0.13-0.23)与0.15(95%可信区间0.08-0.21)log10 cfu/mL/day。
  • 对应II期临床试验中两者灭菌速率分别为0.16(95%可信区间0.13-0.18)与0.11(95%可信区间0.09-0.13)log10 cfu/mL/day。
  • 经灭绝时间与拉丁超立方抽样建模,PaMZ方案3个月和4个月疗程的预期灭菌患者比例分别为40.37%(95%可信区间39.1-41.34)和72.30%(95%可信区间71.41-73.17)。
  • 标准治疗6个月疗程的预期灭菌患者比例为93.67%(95%可信区间93.18-94.13)。

关键数值与推荐

  • PaMZ方案3个月疗程预期灭菌比例40.37%(95%可信区间39.1-41.34)。
  • PaMZ方案4个月疗程预期灭菌比例72.30%(95%可信区间71.41-73.17)。
  • 标准治疗6个月疗程预期灭菌比例93.67%(95%可信区间93.18-94.13)。

临床怎么用

  • 提示PaMZ方案短至3-4个月疗程可能不足以使多数结核患者达到灭菌,临床缩短疗程需谨慎并依赖临床试验验证。

局限性

  • 结论基于中空纤维系统模型与数学建模的预测,并非直接来自患者临床终点数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Animal models have suggested that the combination of pretomanid with pyrazinamide and moxifloxacin (PaMZ) may shorten TB therapy duration to 3-4 months. Here, we tested that in the hollow-fibre system model of TB (HFS-TB). METHODS: A series of HFS-TB experiments were performed to compare the kill rates of the PaMZ regimen with the standard three-drug combination therapy. HFS-TB experiments were performed with bacilli in log-phase growth treated for 28 days, intracellular bacilli treated daily for 28 days and semi-dormant Mycobacterium tuberculosis treated with daily therapy for 56 days for sterilizing effect. Next, time-to-extinction equations were employed, followed by morphism transformation and Latin hypercube sampling, to determine the proportion of patients who achieved a time to extinction of 3, 4 or 6 months with each regimen. RESULTS: Using linear regression, the HFS-TB sterilizing effect rates of the PaMZ regimen versus the standard-therapy regimen during the 56 days were 0.18 (95% credible interval=0.13-0.23) versus 0.15 (95% credible interval=0.08-0.21) log10 cfu/mL/day, compared with 0.16 (95% credible interval=0.13-0.18) versus 0.11 (95% credible interval=0.09-0.13) log10 cfu/mL/day in the Phase II clinical trial, respectively. Using time-to-extinction and Latin hypercube sampling modelling, the expected percentages of patients in which the PaMZ regimen would achieve sterilization were 40.37% (95% credible interval=39.1-41.34) and 72.30% (95% credible interval=71.41-73.17) at 3 and 4 months duration of therapy, respectively, versus 93.67% (95% credible interval=93.18-94.13) at 6 months for standard therapy. CONCLUSIONS: The kill rates of the PaMZ regimen were predicted to be insufficient to achieve cure in less than 6 months in most patients.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Srivastava S, Deshpande D, Magombedze G, et al. Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics. J Antimicrob Chemother. 2020. PMID: 31713607. doi:10.1093/jac/dkz460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。